Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: xanthakis i. BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111. BMC Cancer. 2014. PMID: 24555920 Free PMC article.
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
Makatsoris T, Papakostas P, Kalofonos HP, Xanthakis I, Tsavdaridis D, Aravantinos G, Gogas H, Klouvas G, Kosmidis P, Pectasides D, Fountzilas G. Makatsoris T, et al. Among authors: xanthakis i. Med Oncol. 2007;24(3):301-7. doi: 10.1007/s12032-007-0004-1. Med Oncol. 2007. PMID: 17873305 Clinical Trial.
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.
Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P, Fountzilas G. Razis E, et al. Among authors: xanthakis i. BMC Cancer. 2008 Aug 13;8:234. doi: 10.1186/1471-2407-8-234. BMC Cancer. 2008. PMID: 18700047 Free PMC article.
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G. Skarlos DV, et al. Among authors: xanthakis i. Oncology. 2009;77(2):107-12. doi: 10.1159/000229504. Epub 2009 Jul 21. Oncology. 2009. PMID: 19622901
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA. Bamias A, et al. Among authors: xanthakis i. BMC Cancer. 2010 Feb 18;10:45. doi: 10.1186/1471-2407-10-45. BMC Cancer. 2010. PMID: 20163744 Free PMC article.
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Kalofonos HP, Papakostas P, Makatsoris T, Papamichael D, Vourli G, Xanthakis I, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis I, Samelis G, Syrigos KN, Xiros N, Stavropoulos M, Kosmidis P, Christodoulou C, Linardou H, Skondra M, Pectasides D, Economopoulos T, Fountzilas G. Kalofonos HP, et al. Among authors: xanthakis i. Anticancer Res. 2010 Oct;30(10):4325-33. Anticancer Res. 2010. PMID: 21036759 Clinical Trial.
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G. Pectasides D, et al. Among authors: xanthakis i. BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271. BMC Cancer. 2012. PMID: 22748098 Free PMC article. Clinical Trial.
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumarianou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT. Fountzilas G, et al. Among authors: xanthakis i. J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212. J Transl Med. 2012. PMID: 23092535 Free PMC article.
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilas G, Dimopoulos MA. Bamias A, et al. Among authors: xanthakis i. Ann Oncol. 2013 Apr;24(4):1011-7. doi: 10.1093/annonc/mds583. Epub 2012 Nov 7. Ann Oncol. 2013. PMID: 23136231 Free article. Clinical Trial.
27 results